# Tandem Diabetes Care

> Tandem Diabetes Care makes insulin pumps, automated insulin-delivery software, infusion supplies, and diabetes data tools. Its t:slim X2 and Tandem Mobi systems combine compatible glucose sensors with predictive insulin adjustment, serving people with insulin-dependent diabetes and the clinicians who support them. The Nasdaq-listed company operates internationally and reported $1.015 billion in 2025 sales.

- **Founded:** 2006
- **Headquarters:** San Diego, United States
- **Founders:** Paul DiPerna (Founder; designer of the initial insulin pump)
- **Products:** t:slim X2 insulin pump, Tandem Mobi, Control-IQ+ technology, Tandem Source, Infusion sets, cartridges, and accessories
- **Notable:** Commercialized its first touchscreen t:slim pump in 2012., Introduced remotely updatable t:slim X2 in 2016., The 2019 randomized Control-IQ trial found improved glucose time in range versus sensor-augmented pump therapy.

## Products & services

- **t:slim X2 insulin pump** — Rechargeable touchscreen pump with a 300-unit cartridge, compatible CGM integrations, mobile bolus capability, and remotely updatable software. Availability depends on market and software version.
- **Tandem Mobi** — Compact 200-unit insulin pump controlled through a compatible smartphone, with a physical bolus button, inductive charging, and several wearing options. U.S. commercial launch in February 2024.
- **Control-IQ+ technology** — Predictive automated insulin-delivery software using compatible CGM readings. U.S. indications include type 1 diabetes age 2+ and type 2 diabetes age 18+; device-specific labeling and minimum insulin requirements apply.
- **Tandem Source** — Platform for therapy reports, supply reordering, and access to pump software updates; also supports healthcare-provider data review.
- **Infusion sets, cartridges, and accessories** — Recurring pump supplies plus clips, sleeves, cases, and other accessories.
- **Virtual pump demonstrations** — Interactive demonstrations let prospective users explore pump interfaces; demos do not deliver insulin or replace training.

## Achievements

- Commercialized its first touchscreen t:slim pump in 2012.
- Introduced remotely updatable t:slim X2 in 2016.
- The 2019 randomized Control-IQ trial found improved glucose time in range versus sensor-augmented pump therapy.
- Passed $1 billion in annual sales in 2025.
- Mobi was available in 12 countries outside the United States by September 2026.

## Latest updates

- **2026-09** — Mobi began shipping to eligible customers in 12 countries outside the United States; international Android support remained planned for select countries in 2027.
- **2026-08** — Reported Q2 worldwide sales of $254.6 million and more than 33,000 pump shipments; 10% of U.S. sales came through pharmacy.
- **2026-08** — Q2 results reported FDA clearance and CE Mark for Control-IQ+ use in type 1 diabetes during pregnancy, U.S. Dexcom G7 15-day sensor compatibility for both pumps, and submission of Mobi tubeless capability to the FDA. Submission is not clearance.

## Links

- Website: https://www.tandemdiabetes.com/
- LinkedIn: https://www.linkedin.com/company/tandemdiabetes
- Twitter/X: https://twitter.com/tandemdiabetes
- YouTube: https://www.youtube.com/user/tandemdiabetes
- Instagram: https://www.instagram.com/tandemdiabetes/
- Facebook: https://www.facebook.com/TandemDiabetes
- TikTok: https://www.tiktok.com/@tandemdiabetes

---

Profile page: https://yespress.io/tandem-diabetes-care
Published by YesPress — https://yespress.io
Last updated: 2026-10-23